Mentor Capital's Cancer Immunotherapy Index: First funding tranche to extend investment closes

Mentor Capital, Inc.'s (Pink Sheets:MNTR) first funding tranche to extend its investment in its proprietary Cancer Immunotherapy Index closes today. Cash investment from 1,400 existing shareholders projects to be approximately 20% oversubscribed from target. Company management reservation to fund will be correspondingly reduced to remain within the $1.2 Million seed funding limit. Already authorized follow-on public funding tranches total an additional $125 Million that will also be targeted for investment into the best of the Cancer Immunotherapy Index companies.

By overweighting the investment of this $125 Million into the most promising Index companies, Mentor Capital seeks to exceed the return of the equally weighted CI Index. The Cancer Immunotherapy Index has grown at an annualized 90% rate since its original creation by Mentor Capital twenty-nine weeks ago.

The current ten CI Index companies that Mentor Capital has invested into are: Dendreon (NASDAQ:DNDN), Immunocellular Therapeutics, Ltd. (OTCBB:IMUC), Oncothyreon (NASDAQ:ONTY), Antigenics (NASDAQ:AGEN), Biovest International (BVTI.PK), Celldex Therapeutics (NASDAQ:CLDX), Northwest Biotherapeutics (OTCBB:NWBO), CEL – SCI Corp. (AMEX:CVM) and Generex Biotechnology (NASDAQ:GNBT) as a proxy for its wholly-owned immunotherapeutic subsidiary, Antigen Express, and Quantum Immunologics, Inc. a private company. In addition to actively managing its investment into these companies, Mentor Capital looks to occasionally add emerging companies to the Index as they reach an adequate size or shift their immunotherapy emphasis from infectious disease to the cancer fight.

Level II trading charts, financial and other information on Mentor Capital, plus listings and links to all Cancer Immunotherapy Index companies may be referenced from the company website: www.MentorCapital.com.

SOURCE Mentor Capital, Inc.